10-Q - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

SCHEDULE 13G/A - ContextLogic Inc. (0001822250) (Subject)

10-K/A - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

SCHEDULE 13G - ContextLogic Inc. (0001822250) (Subject)

8-K - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

S-8 - ContextLogic Inc. (0001822250) (Filer)

10-K - ContextLogic Inc. (0001822250) (Filer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

3 - ContextLogic Inc. (0001822250) (Issuer)

3 - ContextLogic Inc. (0001822250) (Issuer)

3 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

OAKLAND, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today announced it will report its fourth quarter and full year 2024 financial results after the close of market on Wednesday, March 12, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Mr. Bajaj and Mr. Goldthorpe will briefly discuss the company's fourth quarter results as well as provide additional commentary on the recently announced strategic investment and commitment made by BC Partners into Context

Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L

OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and nine months ended September 30, 2024. Third Quarter 2024 Financial Highlights Net Loss: Net loss was $1 million, compared to a net loss of $80 million in the third quarter of 2023.As of September 30, 2024, the Company had $33 million in cash and cash equivalents, $117 million in marketable securities and $8 million in prepaid expenses and other current assets (primarily made up of $7 million in restricted cash). Company Outlook Over the last quarter, the Company has created a streamlined administrat

OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2024. Company Update On February 10, 2024, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Qoo10 Inc., a Delaware corporation ("Qoo10 Delaware"), and, for certain specified purposes, Qoo10 Pte. Ltd., a Singapore private limited company and Qoo10 Delaware's parent company ("Qoo10"), pursuant to which (i) the Company agreed to sell substantially all of its assets to Qoo10 Delaware or an affiliate designated by Qoo10 Delaware (such desig

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033.  Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued at

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued a

OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

OAKLAND, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today announced it will report its fourth quarter and full year 2024 financial results after the close of market on Wednesday, March 12, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Mr. Bajaj and Mr. Goldthorpe will briefly discuss the company's fourth quarter results as well as provide additional commentary on the recently announced strategic investment and commitment made by BC Partners into Context

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033.  Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued at

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued a

LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update. To date, four patients have been dosed in the SUNRISE trial with LB-001, LogicBio's investigational, single-administration, adeno-associated virus (AAV) genome editing therapy. In accordance with th

Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L

LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update

LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management. Ms. Paul and Ms. Olson are both seasoned industry experts with extensive experience in the pharmaceutical and biotechnology industries including in the gene therapy and rare disease sectors. "It is an exciting time at LogicBio with ongoing efforts to expand the reach of our G

William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform

Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously

Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously

Barclays reiterated coverage of LogicBio Therapeutics with a rating of Overweight and set a new price target of $8.00 from $24.00 previously

JMP Securities reiterated coverage of LogicBio Therapeutics with a rating of Market Outperform and set a new price target of $16.00 from $17.00 previously

HC Wainwright & Co. initiated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $15.00

JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform and set a new price target of $17.00

JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform and set a new price target of $17.00

JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform

JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00